Noregen™ (CTR-107)
Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
PreclinicalActive
Key Facts
Indication
Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Phase
Preclinical
Status
Active
Company
About RetiNova Therapeutics
RetiNova Therapeutics is pioneering a novel class of regenerative biologics aimed at restoring vision in patients with retinal ischemic diseases. Its lead asset, Noregen™, is a first-in-class, complete norrin mimic that activates developmental pathways to regenerate functional retinal vasculature and neurons, going beyond the symptomatic control of current anti-VEGF standards. The company is targeting the large, underserved markets of DME and RVO, where millions of patients experience progressive vision loss despite frequent injections. RetiNova is a private, preclinical-stage biotech positioned to potentially revolutionize treatment outcomes through disease modification.
View full company profile